Clinical Psychopharmacology: A Master Class
Ross Baldessarini, MD, DSc (hon.)

July 7 – 9, 2017 • Friday-Sunday

See Accreditation

REGISTER NOW

Please note There was an error on the first printed version of the brochure, the correct dates are July 7-9, 2017.

This seminar will address recent clinical research that forms the basis of rational, evidence-based clinical practice in the care of patients with bipolar disorder, major depression, schizophrenia, other psychotic disorders, and severe anxiety disorders. It will emphasize and critically address the evidence base that guides clinical practice in the use of psychotropic medicines to these disorders, considering short-term and long-term efficacy and dosing of antipsychotic, moodstabilizing, antidepressant drugs, and anti-anxiety agents as well as their adverse-effect risks. Participants are expected to be experienced clinicians (psychiatrists, other physicians, nurse practitioners, psychologists, social workers) with curiosity about the procedures and findings of modern clinical and experimental therapeutics research as a sound basis for improved clinical practice. Educational presentation will be in seminar format and include lectures, participant discussion and Q&A.

 

Upon completion of this seminar, participants will be able to:

 

  • Describe and critically evaluate the evolution of clinical psychopharmacology over the past half-century, its current status, and future prospects;
  • Evaluate evidence supporting short- and long-term treatment of psychiatric patients;
  • Evaluate evidence supporting short- and long-term treatment of patients with bipolar disorders;
  • Describe and critically evaluate evidence supporting short- and long-term treatment of patients with major depressive disorder;
  • Describe and critically evaluate evidence supporting short- and long-term treatment of patients with severe anxiety disorders;
  • Assess potentially severe adverse effects of psychotropic drug treatment;
  • Improve skills in avoiding, limiting and managing risk of adverse effects of psychotropic drug treatment;
  • Evaluate treatment practices involving psychotropic drugs and develop strategies to improve clinical practice;
  • Analyze current relationships between treatment with psychotropic drugs and risk of mortality due to suicide and other aspects of increased mortality risks in psychiatric patients;
  • Better integrate psychopharmacology into the comprehensive care of patients;
  • Critically assess advantages and limitations of clinical psychopharmacology;
  • Critically assess the impact of clinical psychopharmacology on theory, training, research, and practice of contemporary clinical mental health professional.

 

SCHEDULE

 

Friday, July 7, 2017

  • Overview & update on modern psychopharmacology: historical development, clinical research methods,major findings, and clinical applications.
  • Evidence for the efficacy and effectiveness of antipsychotic drugs; comparisons of modernand first generation agents.
  • Discussion & questions.

 

Saturday, July 8, 2017

  • Evidence for the efficacy and effectiveness of treatments for acute mania and recurrences of mania, bipolar depression and mixed manic-depressive states.
  • Discussion & questions.
  • Comparisons of lithium and FDA-approved anticonvulsants and antipsychotics for treatment of bipolar disorder patients.
  • Introduction to the pharmacology and short-term clinical use of antidepressants for major depressive and anxiety disorders.
  • Discussion & questions.

 

Sunday, July 9, 2017

  • Long-term use of antidepressants to treat depression and anxiety disorders; managing treatment-resistant depression.
  • Effects of treatment on suicidal risks and overall mortality risks.
  • Discussion & questions.
  • Practical aspects of clinical use of psychotropic drugs; discussion of the current status of clinical psychopharmacology with respect to research, training, and clinical practice.
  • General discussion.